2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ

Önder Kaplan; Mehmet Güney; Murat Yüksel

doi:10.17343/sdutfd.02504

2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ

Abstract

ÖZET Amaç: Amniyosentez girişimlerindeki endikasyonların dağılımı, yaşa göre oranları, girişim işlemleri, hücre kültür sonuçları incelenmektedir. Materyal ve method: Şubat 2003 - Aralık 2011 tarihleri arasında Süleyman Demirel Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum kliniğinde yüksek riskli gebeliklerde karyotip amaçlı yapılan amniyosentez sonuçları retrospektif olarak değerlendirilmiştir. Bulgular: 1586 olgu incelendi. Hastaların yaş aralığı 19–24 yaş % 8 (132/1586), 25–30 yaş % 13 (217/1586), 31–35 yaş % 24 (389/1586), 36–40 yaş % 36 (574/1586), 41–44 yaş % 17 (274/1586) oranında saptandı. Amniyosentezin 15–22 haftalar (17,2±1,4) arasında yapıldığı görüldü. Kromozomal anomali % 3,65 (58/1586) hastada görüldü. Trizomi 21 (Down sendromu) % 1,1 (18/1586) olarak belirlendi. Down sendromu saptanan hastalar 32, 43 yaşları arasında idi. Amniyosentez sonrasında gebelik kaybı % 0,6 (11/1586) olarak saptandı. Sonuçlar: Anomali saptanan olgulara genetik danışmanlık hizmeti verilmiştir. Anahtar Kelimeler: Amniyosentez, Genetik, Kromozomal Anomali, Down Sendromu, Genetik Danışmanlık ABSTRACT Objective: The distribution of indications for amniocentesis attempts, rates by age, intervention methods, cell culture results are analyzed. Material and Methods: Amniocentesis performed for karyotyping in high risk pregnancies in department of Obstetrics and Gynecology, Süleyman Demirel University between 2003 and 2011 are investigated retrospectively. Results: 1586 cases are evaluated. Age of 19–24 8 % (132/1586), age of 25–30 13 % (217/1586), age of 31–35 % 24 (389/1586), age of 36–40 % 36 (574/1586), age of 41–44 % 17 (274/1586) was determined. 15-22 weeks of amniocentesis (17.2 ± 1.4) were made between. 3.65 % of chromosomal abnormalities (58/1586) of the patients had. Trisomy 21 (Down Syndrome) 1.1 % (18/1586) was determined. The patients with Down syndrome, 32 and 43years of age. 0,6 % (11/1586) pregnancy loss after amniocentesis Conclusion: Genetic counseling is provided for all cases. Key Words: Amniocentesis, Genetic, Chromosomal Abnormality, Genetic Counseling

Keywords

Amniyosentez, Genetik, Kromozomal Anomali, Down Sendromu, Genetik Danýþmanlýk

References

Deparpment of Obstetrics ang Gynaecology Tietung Hospital of Anshan Iron and Steel Company: Fetal sex Prediction by chromatin of chorionic villi cells during early pregnancy. Chin Med 1975;1:117-26.
ACOG committee opinion. No. 296. First trimester screening for fetal aneuploidy. Obstet Gynecol 2004;104:215-217
National Collaborating Centre for womens and Childrens Health. Antenatal Care: Routine Care for t h e H e a l t h y p r e g n a n t w o m a n , 2003http://www.rcog.org.uk/resources/Public/pdf/A ntenatal_care.pdff
Biggio JR. First trimester ultrasound screening for fetal aneuploidy and middle cerebral artery Doppler assessment for fetal alloimmunization. Curr Opin Pediatr. 2005;17(6):713-9
Eddleman KA, Malone FD,Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y. Pregnancy loss rates after m i d t r i m e s t e r a m n i o c e n t e s i s . O b s t e t Gynaecol.2006;108(5):1067-72.
Cederholm M, Haglund B, Axelsson O. Maternal complications following amnicentesis and chrorionic villus sampling for prenatal karyityping. Br J Obstet Gynaecol.2003;110(4):392-9.
Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Sculpher M. Screening for Downs syndrome:effects, safety and cost effectiveness of first and second trimester strategiess. BMJ.2001;25;323(7310):423-5.
Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Downs syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Br J Obstet Gynaecol.1996;103(5)407-12.

Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal- translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-346
Benn PA. Advances in prenatal screening for Down syndrome: II first trimester testing,integrated testing, and future directions. Clin Chim Acta 2002;324: 1-11
Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003;110:281-286
Sjögren B, Uddenberg N. Decision making during the prenatal diagnostic procedur. A questionnaire and interview study of 211 women partipating in prenatal diagnosis. Prenat Diagn. 1989,9;263-273.
Bubb JA, Matthews AL. Whats new in prenatal screening and diagnosis? Prim Care 2004;31:561-82
The Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT) Group. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998;24351:242-247
Tabor A, Madsen M, Obel E, Philip J, Bang J, Norgaard- Pedersen B: Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;1:12871293.
NICHD National Registry for amniocentesis study group: midtrimester amniocentesis for prenatal diagnosis: safety and accuracy.JAMA 1976; 236:14711476.
Blackwell SC, Abundis MG, Nehra PC. FÝve-year experince with midtrimester amniocentesis performed by a single group of obstetricians-gynecologists at a community hospital. Am J Obstet Gynecol 2002;186(6):1130-2.
Marthin T, Liedgren S, Hammar M. Transplacental needle passage and other risk-faktors associated with second trimester amniocentesis. Acta Obstet Gynecol Scand. 1997;76(8):728-32.

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Önder Kaplan

Mehmet Güney

Murat Yüksel

Publication Date

December 30, 2012

Submission Date

March 20, 2012

Acceptance Date

-

Published in Issue

Year 2012 Volume: 19 Number: 4

DOI

https://doi.org/10.17343/sdutfd.02504

IZ

https://izlik.org/JA45TH52FT

Cite

RIS / Bibtex

APA

Kaplan, Ö., Güney, M., & Yüksel, M. (2012). 2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ. Medical Journal of Süleyman Demirel University, 19(4), 144-147. https://doi.org/10.17343/sdutfd.02504

AMA

1.Kaplan Ö, Güney M, Yüksel M. 2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ. Med J SDU. 2012;19(4):144-147. doi:10.17343/sdutfd.02504

Chicago

Kaplan, Önder, Mehmet Güney, and Murat Yüksel. 2012. “2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ”. Medical Journal of Süleyman Demirel University 19 (4): 144-47. https://doi.org/10.17343/sdutfd.02504.

EndNote

Kaplan Ö, Güney M, Yüksel M (December 1, 2012) 2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ. Medical Journal of Süleyman Demirel University 19 4 144–147.

IEEE

[1]Ö. Kaplan, M. Güney, and M. Yüksel, “2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ”, Med J SDU, vol. 19, no. 4, pp. 144–147, Dec. 2012, doi: 10.17343/sdutfd.02504.

ISNAD

Kaplan, Önder - Güney, Mehmet - Yüksel, Murat. “2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ”. Medical Journal of Süleyman Demirel University 19/4 (December 1, 2012): 144-147. https://doi.org/10.17343/sdutfd.02504.

JAMA

1.Kaplan Ö, Güney M, Yüksel M. 2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ. Med J SDU. 2012;19:144–147.

MLA

Kaplan, Önder, et al. “2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ”. Medical Journal of Süleyman Demirel University, vol. 19, no. 4, Dec. 2012, pp. 144-7, doi:10.17343/sdutfd.02504.

Vancouver

1.Önder Kaplan, Mehmet Güney, Murat Yüksel. 2. TRİMESTER GENETİK TARAMA AMNİYOSENTEZ 1586 OLGUNUN DEĞERLENDİRİLMESİ. Med J SDU. 2012 Dec. 1;19(4):144-7. doi:10.17343/sdutfd.02504